Market News

Sei Investments Company Trimmed By $3.96 Million Its Bb&T (BBT) Position; 8 Analysts Covering Arena Pharmaceuticals, Inc. (ARNA)

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Logo

Among 10 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Arena Pharmaceuticals had 27 analyst reports since October 28, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, April 18. Needham upgraded the stock to “Buy” rating in Tuesday, March 20 report. Cantor Fitzgerald maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Monday, February 26 with “Buy” rating. Cantor Fitzgerald maintained it with “Buy” rating and $37.0 target in Wednesday, November 8 report. As per Wednesday, July 12, the company rating was maintained by Citigroup. The company was maintained on Thursday, January 4 by Cantor Fitzgerald. The firm has “Buy” rating given on Tuesday, March 20 by Wells Fargo. The rating was maintained by Citigroup with “Buy” on Tuesday, February 27. Cantor Fitzgerald maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Thursday, June 29 with “Buy” rating. The stock has “Buy” rating by Cantor Fitzgerald on Wednesday, March 14. See Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) latest ratings:

09/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $65.0000 Maintain
18/04/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $65.0000 Maintain
21/03/2018 Broker: Citigroup Rating: Buy New Target: $62.0
20/03/2018 Broker: Wells Fargo Rating: Buy New Target: $60.0 Maintain
20/03/2018 Broker: J.P. Morgan Rating: Hold New Target: $48.0
20/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $64.0 Maintain
20/03/2018 Broker: Needham Old Rating: Hold New Rating: Buy Upgrade
14/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $45.0 Maintain
26/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $45.0 Maintain
27/02/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $37 New Target: $55 Maintain

Sei Investments Company decreased Bb&T Corp (BBT) stake by 13.24% reported in 2017Q4 SEC filing. Sei Investments Company sold 80,828 shares as Bb&T Corp (BBT)’s stock rose 2.32%. The Sei Investments Company holds 529,846 shares with $26.37 million value, down from 610,674 last quarter. Bb&T Corp now has $42.98 billion valuation. The stock decreased 0.74% or $0.41 during the last trading session, reaching $55.12. About 1.46 million shares traded. BB&T Corporation (NYSE:BBT) has risen 16.87% since May 23, 2017 and is uptrending. It has outperformed by 5.32% the S&P500.

More notable recent Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) news were published by: Seekingalpha.com which released: “Arena Pharmaceuticals’ (ARNA) CEO Presents at UBS Global Healthcare Brokers Conference (Transcript)” on May 22, 2018, also Seekingalpha.com with their article: “Arena Pharmaceuticals’ (ARNA) CEO Amit Munshi presents at Bank of America Merrill Lynch Healthcare Brokers …” published on May 18, 2018, Seekingalpha.com published: “Arena Pharmaceuticals’ (ARNA) CEO Amit Munshi on Q1 2018 Results – Earnings Call Transcript” on May 15, 2018. More interesting news about Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: AstraZeneca’s Q1, Novartis-Amgen Migraine Drug Approved” published on May 18, 2018 as well as Globenewswire.com‘s news article titled: “Report: Developing Opportunities within Haemonetics, Arena Pharmaceuticals, Xperi, MoneyGram International, Boot …” with publication date: May 15, 2018.

The stock increased 0.74% or $0.34 during the last trading session, reaching $46.54. About 217,939 shares traded. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has risen 169.40% since May 23, 2017 and is uptrending. It has outperformed by 157.85% the S&P500.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company has market cap of $2.28 billion. The companyÂ’s proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It currently has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

Since January 19, 2018, it had 0 buys, and 16 selling transactions for $25.26 million activity. On Monday, February 5 QUBEIN NIDO R sold $1.15M worth of BB&T Corporation (NYSE:BBT) or 21,025 shares. The insider KING KELLY S sold $4.35 million. $1.25 million worth of BB&T Corporation (NYSE:BBT) was sold by Starnes Clarke R III. 3,116 shares valued at $167,146 were sold by Standridge Brantley J on Thursday, April 26. The insider Powell Cynthia B sold $151,504. Yates William Rufus also sold $882,345 worth of BB&T Corporation (NYSE:BBT) shares. $3.66M worth of stock was sold by DUCK BARBARA F on Wednesday, April 25.

Analysts await BB&T Corporation (NYSE:BBT) to report earnings on July, 19. They expect $1.01 EPS, up 29.49% or $0.23 from last year’s $0.78 per share. BBT’s profit will be $787.55 million for 13.64 P/E if the $1.01 EPS becomes a reality. After $0.97 actual EPS reported by BB&T Corporation for the previous quarter, Wall Street now forecasts 4.12% EPS growth.

Sei Investments Company increased Lgi Homes Inc (NASDAQ:LGIH) stake by 4,373 shares to 26,268 valued at $1.97M in 2017Q4. It also upped Trimble Inc (NASDAQ:TRMB) stake by 55,533 shares and now owns 102,547 shares. Amc Networks Inc (NASDAQ:AMCX) was raised too.

Investors sentiment increased to 1.15 in Q4 2017. Its up 0.22, from 0.93 in 2017Q3. It improved, as 41 investors sold BBT shares while 269 reduced holdings. 96 funds opened positions while 261 raised stakes. 479.66 million shares or 4.23% less from 500.82 million shares in 2017Q3 were reported. Eaton Vance Mngmt stated it has 1.34M shares or 0.16% of all its holdings. 3.58M were reported by Morgan Stanley. Cambridge owns 7,242 shares. Lakeview Limited accumulated 8,098 shares. Rhumbline Advisers accumulated 1.42 million shares. Parsec Mgmt accumulated 0.17% or 51,812 shares. Cetera Advisor Netwr Limited Liability Company has invested 0.08% in BB&T Corporation (NYSE:BBT). Argent has invested 0.86% in BB&T Corporation (NYSE:BBT). Keybank Natl Association Oh, Ohio-based fund reported 26,077 shares. Old Second Bancshares Of Aurora has 0.72% invested in BB&T Corporation (NYSE:BBT). Burke & Herbert Bancorp holds 5,637 shares. Thompson Davis reported 790 shares. Coastline Tru reported 46,840 shares. Hartford Invest holds 0.17% or 185,354 shares. Wellington Management Ltd Liability Partnership accumulated 7.46 million shares or 0.08% of the stock.

Another recent and important BB&T Corporation (NYSE:BBT) news was published by Bizjournals.com which published an article titled: “Top Florida banker’s push for regulatory relief pays off” on May 23, 2018.

BB&T Corporation (NYSE:BBT) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *